According to Reuters on November 3, citing the Bahraini news agency, Bahrain has urgently approved the injection of China’s candidate new crown vaccine for front-line workers from November 3, which is currently in phase III trial stage. The phase III trials of the candidate vaccine in the United Arab Emirates, Egypt, Bahrain and Jordan are nearing the end, according to the report. The vaccine is a cooperative project between China Biotechnology Group, a subsidiary of Sinopharm group, and 42 group, an artificial intelligence and cloud computing enterprise headquartered in Abu Dhabi. In a commentary released by the Bahraini news agency, Bahraini health minister fayika bint said Saleh said the use of the vaccine was in line with Bahrain’s special licensing requirements for emergency situations. < / P > < p > she said, “the results of phase I and phase II clinical trials have shown that the vaccine is safe and effective”, and that phase III trials are proceeding smoothly without serious side effects. Ashesh Koch, chief executive of the 42 group of healthcare companies, said last month that the vaccine has been given to more than 31000 people in these countries. According to the report, Sheikh Muhammad bin Rashid al Maktoum, vice president and Prime Minister of the United Arab Emirates and emirate of Dubai, recently posted a photo on twitter, in which he was receiving a new crown vaccine.